182 related articles for article (PubMed ID: 27590580)
1. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus.
Dreyer T; Nicholson S; Ely A; Arbuthnot P; Bloom K
Biochem Biophys Res Commun; 2016 Sep; 478(4):1563-8. PubMed ID: 27590580
[TBL] [Abstract][Full Text] [Related]
2. A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA.
Bloom K; Ely A; Arbuthnot P
Methods Mol Biol; 2017; 1540():85-95. PubMed ID: 27975310
[TBL] [Abstract][Full Text] [Related]
3. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric
Smith T; Singh P; Chmielewski KO; Bloom K; Cathomen T; Arbuthnot P; Ely A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372550
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.
Bloom K; Ely A; Mussolino C; Cathomen T; Arbuthnot P
Mol Ther; 2013 Oct; 21(10):1889-97. PubMed ID: 23883864
[TBL] [Abstract][Full Text] [Related]
5. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
7. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.
Ely A; Moyo B; Arbuthnot P
Mol Ther; 2016 Apr; 24(4):671-7. PubMed ID: 26916283
[TBL] [Abstract][Full Text] [Related]
8. Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches.
Kumar M; Follenzi A; Garforth S; Gupta S
Antivir Ther; 2012; 17(3):519-28. PubMed ID: 22300804
[TBL] [Abstract][Full Text] [Related]
9. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection.
Ely A; Singh P; Smith TS; Arbuthnot P
Adv Drug Deliv Rev; 2021 Jan; 168():134-146. PubMed ID: 32485207
[TBL] [Abstract][Full Text] [Related]
10. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication.
Weber ND; Stone D; Sedlak RH; De Silva Feelixge HS; Roychoudhury P; Schiffer JT; Aubert M; Jerome KR
PLoS One; 2014; 9(5):e97579. PubMed ID: 24827459
[TBL] [Abstract][Full Text] [Related]
11. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection.
Zhang Y; Mao R; Yan R; Cai D; Zhang Y; Zhu H; Kang Y; Liu H; Wang J; Qin Y; Huang Y; Guo H; Zhang J
PLoS One; 2014; 9(10):e110442. PubMed ID: 25337821
[TBL] [Abstract][Full Text] [Related]
12. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.
Chen J; Zhang W; Lin J; Wang F; Wu M; Chen C; Zheng Y; Peng X; Li J; Yuan Z
Mol Ther; 2014 Feb; 22(2):303-311. PubMed ID: 24025750
[TBL] [Abstract][Full Text] [Related]
13. miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Xing T; Zhu J; Xian J; Li A; Wang X; Wang W; Zhang Q
Life Sci; 2019 Feb; 219():199-208. PubMed ID: 30615846
[TBL] [Abstract][Full Text] [Related]
14. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210.
Zhang GL; Li YX; Zheng SQ; Liu M; Li X; Tang H
Antiviral Res; 2010 Nov; 88(2):169-75. PubMed ID: 20728471
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
[TBL] [Abstract][Full Text] [Related]
16. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
17. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.
Ogura N; Watashi K; Noguchi T; Wakita T
Biochem Biophys Res Commun; 2014 Sep; 452(3):315-21. PubMed ID: 25150444
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples.
Taranta A; Tien Sy B; Zacher BJ; Rogalska-Taranta M; Manns MP; Bock CT; Wursthorn K
J Clin Virol; 2014 Aug; 60(4):354-60. PubMed ID: 24890819
[TBL] [Abstract][Full Text] [Related]
19. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
Ely A; Arbuthnot P
Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.
Mowa MB; Crowther C; Ely A; Arbuthnot P
Biomed Res Int; 2014; 2014():718743. PubMed ID: 25003129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
